![](/img/cover-not-exists.png)
702 - 4-hydroxyandrostenedione (4-OHA) as third-line endocrine therapy in postmenopausal patients with advanced breast cancer
C.S. Gennatas, J. Psychogios, C. Dardoufas, N. Tsavaris, S. AthanasiadisVolume:
33
Year:
1997
Language:
english
DOI:
10.1016/s0959-8049(97)85301-4
File:
PDF, 215 KB
english, 1997